Ribeiro Guerra, Maximiliano Coignard, Juliette Eon-Marchais, Séverine Dondon, Marie-Gabrielle Le Gal, Dorothée Beauvallet, Juana Mebirouk, Noura Belotti, Muriel Caron, Olivier Gauthier-Villars, Marion
...
Published in
Breast Cancer Research
BackgroundDiagnostic ionizing radiation is a risk factor for breast cancer (BC). BC risk increases with increased dose to the chest and decreases with increased age at exposure, with possible effect modification related to familial or genetic predisposition. While chest X-rays increase the BC risk of BRCA1/2 mutation carriers compared to non-carrie...
Ferraro, Emanuela Drago, Joshua Z. Modi, Shanu
Published in
Breast Cancer Research
The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibody-drug conjugates (ADCs) are a class of therapeut...
Lal, Jessica Castrillon Townsend, Madeline G. Mehta, Anita K. Oliwa, Madisson Miller, Eric Sotayo, Alaba Cheney, Emily Mittendorf, Elizabeth A. Letai, Anthony Guerriero, Jennifer L.
...
Published in
Breast Cancer Research
BackgroundThe heterogeneity of the breast tumor microenvironment (TME) may contribute to the lack of durable responses to immune checkpoint blockade (ICB); however, mouse models to test this are currently lacking. Proper selection and use of preclinical models are necessary for rigorous, preclinical studies to rapidly move laboratory findings into ...
Jones, Gieira S. Hoadley, Katherine A. Olsson, Linnea T. Hamilton, Alina M. Bhattacharya, Arjun Kirk, Erin L. Tipaldos, Heather J. Fleming, Jodie M. Love, Michael I. Nichols, Hazel B.
...
Published in
Breast Cancer Research
BackgroundAfrican American women have the highest risk of breast cancer mortality compared to other racial groups. Differences in tumor characteristics have been implicated as a possible cause; however, the tumor microenvironment may also contribute to this disparity in mortality. Hepatocyte growth factor (HGF) is a stroma-derived marker of the tum...
Chew, Nicole J. Lim Kam Sian, Terry C. C. Nguyen, Elizabeth V. Shin, Sung-Young Yang, Jessica Hui, Mun N. Deng, Niantao McLean, Catriona A. Welm, Alana L. Lim, Elgene
...
Published in
Breast Cancer Research
BackgroundParticular breast cancer subtypes pose a clinical challenge due to limited targeted therapeutic options and/or poor responses to the existing targeted therapies. While cell lines provide useful pre-clinical models, patient-derived xenografts (PDX) and organoids (PDO) provide significant advantages, including maintenance of genetic and phe...
Ranjan, Manish Lee, Oukseub Cottone, Gannon Mirzaei Mehrabad, Elnaz Spike, Benjamin T. Zeng, Zexian Yadav, Shivangi Chatterton, Robert Kim, J. Julie Clare, Susan E.
...
Published in
Breast Cancer Research
BackgroundThe ovarian hormones estrogen and progesterone (EP) are implicated in breast cancer causation. A specific consequence of progesterone exposure is the expansion of the mammary stem cell (MSC) and luminal progenitor (LP) compartments. We hypothesized that this effect, and its molecular facilitators, could be abrogated by progesterone recept...
Garay, Joseph P. Smith, Rebecca Devlin, Kaylyn Hollern, Daniel P. Liby, Tiera Liu, Moqing Boddapati, Shanta Watson, Spencer S. Esch, Amanda Zheng, Ting
...
Published in
Breast Cancer Research
BackgroundHER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these targeted therapies is a common problem, but the mechanisms by which resistance occurs remain incompletely defined. One mechanism that has been proposed is through mutation of genes in th...
Cheng, Ting-Yuan David Omilian, Angela R. Yao, Song Zhang, Weizhou Datta, Susmita Bshara, Wiam Ondracek, Rochelle Payne Davis, Warren Liu, Song Hong, Chi-Chen
...
Published in
Breast Cancer Research
BackgroundThe mechanistic target of rapamycin (mTOR) pathway promoted by positive energy imbalance and insulin-like growth factors can be a mechanism by which obesity influences breast cancer risk. We evaluated the associations of body fatness with the risk of breast cancer varied with phosphorylated (p)-mTOR protein expression, an indication of th...
Mohammed, Samia Shamseddine, Achraf A. Newcomb, Benjamin Chavez, Ronald S. Panzner, Tyler D. Lee, Allen H. Canals, Daniel Okeoma, Chioma M. Clarke, Christopher J. Hannun, Yusuf A.
...
Published in
Breast Cancer Research
BackgroundDoxorubicin (Dox) is a widely used chemotherapy, but its effectiveness is limited by dose-dependent side effects. Although lower Dox doses reduce this risk, studies have reported higher recurrence of local disease with no improvement in survival rate in patients receiving low doses of Dox. To effectively mitigate this, a better understand...
His, Mathilde Lajous, Martin Gómez-Flores-Ramos, Liliana Monge, Adriana Dossus, Laure Viallon, Vivian Gicquiau, Audrey Biessy, Carine Gunter, Marc J. Rinaldi, Sabina
...
Published in
Breast Cancer Research
BackgroundWhile mammographic density is one of the strongest risk factors for breast cancer, little is known about its determinants, especially in young women. We applied targeted metabolomics to identify circulating metabolites specifically associated with mammographic density in premenopausal women. Then, we aimed to identify potential correlates...
